

**Care firing on all cylinders across its operational metrics- increased cost base revises forecast and TP down, however we upgrade to an “Overweight” recommendation after a price decline of 17% in 6m.**

Care ended FY24 with a net income of SAR 298.2mn (up 11.7% Y/Y) while reporting healthy pulse readings across key operational metrics from patient growths supported by a 54% increase in recent capacity additions from since Q4-23, and 11.6pcp increase in Q4-24 utilization rates (Y/Y). Q4-24 however, displayed an increased cost base for Care, we expect some of which to carry on in the medium term as AISalam ramps up, and as management undergoes their M&A strategy. In absence of net positive one-offs, we estimate that Care's Q4-24 net income of SAR 87.19mn (up 37.3% Y/Y and 44.9% Q/Q) would be normalized at the range of SAR 60.0mn (down 2.4% Y/Y and flat Q/Q), as a result of a 41.2% increase in SG&A's and 230bps decline in GPMs Y/Y. We expect some of these costs to carry on, to drive our outlook to revise down from a previously forecasted net income CAGR of 16.2% to 14.9% through FY23-29E. We revise our TP down by 7% to **SAR 188.0 per share** at an upgraded recommendation at “**Overweight**” on the back of an AISalam turnaround, improving utilization rates, and future expansions.

**Display of strong business momentum in FY24 across various operational metrics in a sign of growth for Care; signs of heightened cost base apparent by Q4-24:** Care's net income for 2024 reached a bottom line of SAR 298.16mn (up 11.7% Y/Y); FY24 results were supported by capacity additions; Jeddah-Balad (175 beds) and Haram branches (100 beds), which came in late FY23, as well as the AISalam acquisition (100 beds), and launch of the Mental Health Center (20 beds). In support from new facility additions, Care served 742.5 thousand patients in 2024, a 14% increase Y/Y. Capacity increases and patient volumes drove a yearly revenue growth of 19.6% Y/Y to reach SAR 1.29bn for FY24, in support of increased referrals from MoH and GOSI patients. Despite the positive operational metrics, Q4-24 came with heightened cost base (some sustainable in the short term), and reversals to drive Q4-24 net income to reach SAR 87.19mn (up 37.3% Y/Y and 44.9% Q/Q). Estimated normalized results, after adjusting for the net positive c. SAR 28mn in other income and ECL provisions, as well as one off costs, would drive net income to near SAR 60mn; down 2.4% Y/Y and flat Q/Q as gross margins dip 230bps Y/Y to 33.3% and SG&A increases 41.2% Y/Y as a result of higher salaries, AISalam consolidation, and advisory fees. Heightened ECL provisions at c. SAR 16mn are however expected to reverse by H1-25.

**FY25-27 expected performance driven by capacity ramp ups, and potential price increases; our downward revised net income FY24-27E CAGR forecast of 9.1% to reflect changes in cost base:**

Care ended FY24E at an increased capacity of c. 1,128 after adding AISalam hospital to its portfolio (class C hospital at 100 beds capacity), and the ReLib Mental Health Center (20 beds). When considering the Q4-23 additions of the Haram branch (100 beds) and Al-Balad branch (175 beds), Care's built up capacity grew by an estimated 54% from pre Q4-23; while Malaz branch increased its operational capacity during the year as well. The capacity additions, turnaround of AISalam, potential price increases by FY25's end and mid FY26, along with the additional new services at Care are expected to carry the expected revenue CAGR of 11.2% throughout FY24-27E. We expect yearly utilization levels to improve from FY24's 68.1%, as capacity additions and the completion of the National Guard Contract pressurized utilizations up until Q3-24, and then supported by the Prince Sultan Military Medical City contract secured in Q2-24 to have utilization reach a healthy 79.4% in Q4-24. Furthermore, AISalam Hospital showed quick signs of improvement as it nearly broke even in December, while management is also in talks with insurance clients to revise prices for the underutilized facility.

On the other hand, our future outlook on Care is revised to reflect the negative surprises in gross margins (35.1% vs our previously estimated 36.3% for FY24) and FY24 SG&As reaching 12.7% higher than our estimates. Taking into account one-off fees for idle land in Narjis, cyclical advisory fees, and ECL provisions, as well as Zakat and legal provision reversals, our net income estimate for FY25E was revised down from SAR 340mn to SAR 284.8mn due to tightened gross margins and increased SG&As (expected net income at a 4.5% decline Y/Y as FY24 was supported by a SAR 29mn zakat reversal and SAR 49mn in reversal-supported other income). Our medium term net income forecasts reach a FY24-27E CAGR of 9.1%, supported by new capacity and services while pressurized by ramp ups and costs of expansions.

**Table 1. Changes in AJC estimates**

	FY25 Revised	FY25 previous	Difference	FY26 Revised	FY26 Previous	Difference
Revenue	1,473	1,511	-2%	1,623	1,650	-2%
Gross profit	512	537	-5%	571	591	-3%
GP Margin	34.7%	35.5%	-80bps	35.2%	35.8%	-60bps
Op Income	320	368	-13%	381	416	-8%
Op margin	21.8%	24.3%	-260bps	23.5%	25.2%	-170bps
Net Income	285	341	-16%	337	383	-12%
NI Margin	19.3%	22.6%	-330bps	20.8%	23.2%	-240bps

Source: Company reports, Aljazira Capital

<b>Recommendation</b>	<b>Overweight</b>
<b>Target Price (SAR)</b>	<b>188.0</b>
<b>Upside / (Downside)*</b>	<b>12.6%</b>

Source: Tadawul \*prices as of 05<sup>th</sup> of March 2025

#### Key Financials

in SAR mn, (unless specified)	FY24	FY25E	FY26E	FY27E
Revenue	1,293.7	1,473.4	1,623.2	1,780.1
Growth %	19.6%	13.9%	10.2%	9.7%
Net Income	298.1	284.8	337.0	387.1
Growth %	23.7%	-4.5%	18.3%	14.9%
EPS	6.65	6.35	7.51	8.63
DPS	2.0*	2.0	2.25	2.25

Source: Company reports, Aljazira Capital \*Expected

#### Key Ratios

	FY24	FY25E	FY26E	FY27E
Gross Margin	35.1%	34.7%	35.2%	35.7%
OP Margin	22.9%	21.8%	23.5%	24.5%
Net Margin	23.0%	19.3%	20.8%	21.7%
EBITDA Margin	27.3%	26.4%	29.3%	30.5%
RoE	17.7%	19.3%	16.4%	17.4%
P/E (x)	25.08	26.55	22.24	19.36
P/B (x)	4.60	4.12	3.65	3.21
EV/EBITDA (x)	21.35	19.34	15.91	13.78
Dividend Yield	1.2%	1.2%	1.3%	1.4%


Source: Company reports, Aljazira Capital

#### Key Market Data

Market Cap (SAR bn)	7.5
YTD%	0%
52 weeks (High)/(Low)	160.8/157.0
Share Outstanding (bn)	44.85

Source: Company reports, Aljazira Capital

#### Price Performance



Source: Tadawul, Aljazira Capital

Equity Analyst

Ibrahim Elaiwat

+966 11 2256115


i.elaiwat@Aljaziracapital.com.sa

**FY28 Narjis expansion (400 beds) to drive Care's longer term performance to an expected FY24-29 net income CAGR of 13.2%:** The Narjis expansion, which has begun construction after an idle land penalty, is guided to be completed by end of 2027, and operational by FY28 to roll out in two phases. We expect the expansion to support a forecasted long term revenue and net income CAGRs of 13.1%, and 13.2% respectively (FY24-29). The two phase opening of Narjis is expected to roll out into FY29, while ramping up into FY30 where we expect gross profit margins to normalize at 35.7% after an expansion-pressurized gross margin of 34.7% in FY28. Upside and downside risks are present in Care's M&A strategy which intends to add to its portfolio in the coming years. Management has indicated that it is not a part of their strategy to focus on C class hospitals, but are open to opportunistic M&As. Our long term outlook from our previous FY23-29 CAGR forecast has come down from 16.2% to 14.9% in light of heightened costs mainly from hirings, and some from cyclical advisory fees.

**Care financially positioned for more M&A activity, while we expect dividend policy to remain locked during its expansionary phase:** A negative net debt to equity, improving working capital (net), and future cash flows are expected to support the M&A strategy while maintaining a dividend payout with little expected increase from the previous range of SAR 1.0-2.0 per share. Care's cash and cash equivalent holdings are supported by 12% of total assets being income generating Murabaha holdings (FY24), which decreased from SAR 385mn to SAR 303mn Y/Y (estimated EIR of 5.7%). Its cash conversion cycle, as per management, has also decreased from 157 days to 124 days (net); though gross receivables have increased by 42% to 934mn by FY24's end from receivables coming in from AISalam and slower collections from insurance and GOSI clients. Management however expects that AISalam's delayed collections should not be of issue due to Care's relationship with their clients. We forecast dividends to remain at a range of SAR 2.0 to 2.5 per share till Care's foreseeable expansions are taking place until FY28.


**AJC view and valuation:** Care displays healthy pulse readings across its operational metrics from recent capacity increases (54% increase in recent additions from since Q3-24), patient growth (14% Y/Y), and signs of normalizing utilization rates (79.4% by Q4-24). With the new capacities and services along with potential price increases driving short term performance; Care also possesses long term growth levers through its 400 bed Narjis expansion (35% increase in capacity) expected to be operational by early FY28. Our financial outlook on Care, however, was revised down to reflect the larger than expected costs of these expansions. Heightened G&A's, tighter gross margins are expected to improve gradually while driving our long term net income forecast of a CAGR of 13.2% (FY24-29). Care's cash and debt position and management experience is promising towards more mergers and acquisitions to be announced in the future to expand Care's portfolio. We value the stock at 50% DCF (WACC=8.8 and terminal growth rate = 2.5%) and 50% PE (29.0x on FY25-26 averages) to downwardly revise our TP to **SAR 188.0 per share** by 7% from our previous TP, while upgrading to an **"Overweight"** recommendation on the stock ahead of potentials in an AISalam turnaround, improving utilization rates, and future expansions.

**Fig 1: Announced capacity additions to extend net income growth to FY24-29E CAGR of 13.2%**




Source: Company presentations, AlJazira Capital Research  
 \*Including Malaz built up capacity, Haram and AlBalad added end of FY24 \*\*Narjis to roll out in two phases

**Fig 2: Future growth supported by capacity expansions, utilization improvement, with potential M&A activity to reshape trajectory**



Source: Company presentations, AlJazira Capital Research

**Fig 3: Expansionary activity to weigh on margins**



Source: Company presentations, AlJazira Capital Research



### Key Financials

Amount in USD mn, unless otherwise specified	2023	2024	2025E	2026E	2027E	2028E	2029E	2030E
<b>Income statement</b>								
Revenues	1,081.8	1,293.7	1,473.4	1,623.2	1,780.1	2,069.1	2,398.6	2,706.1
Y/Y	17.8%	19.6%	13.9%	10.2%	9.7%	16.2%	15.9%	12.8%
Cost	(712.2)	(839.6)	(961.8)	(1,051.9)	(1,144.8)	(1,351.8)	(1,555.6)	(1,740.8)
Gross profit	369.6	454.1	511.5	571.3	635.3	717.3	843.1	965.3
GPM	34.2%	35.1%	34.7%	35.2%	35.7%	34.7%	35.1%	35.7%
Selling & distribution expense	(8.5)	(11.3)	(12.0)	(13.3)	(14.4)	(16.9)	(19.6)	(21.9)
General & administration expense	(118.8)	(161.8)	(180.0)	(175.8)	(183.8)	(199.3)	(211.9)	(215.9)
Other expenses/income	4.4	15.9	1.0	(0.8)	(0.9)	(2.1)	-	-
Operating profit	246.7	296.9	320.5	381.4	436.2	499.1	611.6	727.5
Y/Y	24.3%	20.3%	8.0%	19.0%	14.4%	14.4%	22.5%	19.0%
Operating margin	22.8%	22.9%	21.8%	23.5%	24.5%	24.1%	25.5%	26.9%
Net Finance and other cost	17.9	(3.3)	(7.8)	(8.0)	(7.2)	(5.0)	1.3	11.1
Income before zakat	264.6	293.6	312.7	373.4	428.9	494.1	612.9	738.6
Zakat	(23.7)	4.5	(30.6)	(36.6)	(42.0)	(48.4)	(60.1)	(72.4)
Net income	240.9	298.2	282.1	336.8	386.9	445.7	552.8	666.3
Y/Y	41.7%	23.8%	-5.4%	19.4%	14.9%	15.2%	24.0%	20.5%
Net Margin	22.3%	23.0%	19.1%	20.8%	21.7%	21.5%	23.0%	24.6%
EPS	5.37	6.66	6.29	7.51	8.63	9.94	12.33	14.86
DPS	2.00	2.00	2.08	2.25	2.33	2.48	3.33	4.01
<b>Balance sheet</b>								
<b>Assets</b>								
Cash & bank balance	694	567	437	341	298	453	853	1,351
Other current assets	53	58	61	65	69	73	77	82
Receivables	532	605	681	741	801	917	1,046	1,162
Property & Equipment	822	1,108	1,381	1,650	1,915	2,027	1,999	1,969
Other non-current assets	114	165	165	165	165	165	165	165
Total assets	2,214	2,502	2,725	2,962	3,247	3,634	4,141	4,728
<b>Liabilities &amp; owners' equity</b>								
Trade and Other Payables	228	248	288	319	352	421	491	556
Other current liabilities	120	101	92	93	92	94	99	109
Long-term loans	262	244	273	242	210	175	186	198
Total other non-current liabilities	151	280	253	254	257	274	290	305
Paid -up capital	449	449	449	449	449	449	449	449
Statutory reserves	186	-	-	-	-	-	-	-
Retained earnings	819	1,215	1,404	1,640	1,922	2,257	2,660	3,147
Total owners' equity	1,453	1,630	1,819	2,054	2,337	2,671	3,075	3,561
Total equity & liabilities	2,214	2,502	2,725	2,962	3,248	3,634	4,141	4,728
<b>Cashflow statement</b>								
CAPEX	(153)	(342)	(363)	(378)	(386)	(240)	(102)	(102)
Operating activities	467	245	330	418	482	528	629	755
Investing activities	(625)	(193)	(260)	(328)	(336)	(290)	(352)	(402)
Financing activities	138	(93)	(101)	(136)	(139)	(134)	(126)	(156)
<b>Key fundamental ratios</b>								
<b>Liquidity ratios</b>								
Current ratio (x)	6.4	7.2	7.2	7.2	7.3	7.1	7.0	7.1
Quick ratio (x)	3.5	3.4	2.9	2.6	2.5	2.7	3.2	3.8
<b>Profitability ratios</b>								
Gross profit margin	34.2%	35.1%	34.7%	35.2%	35.7%	34.7%	35.1%	35.7%
Operating margin	22.8%	22.9%	21.8%	23.5%	24.5%	24.1%	25.5%	26.9%
EBITDA margin	26.9%	27.3%	26.4%	29.3%	30.5%	29.7%	30.5%	31.4%
Net profit margin	22.3%	23.0%	19.1%	20.8%	21.7%	21.5%	23.0%	24.6%
Return on assets	10.4%	12.3%	12.6%	10.8%	11.8%	12.5%	13.0%	14.2%
Return on equity	14.2%	17.7%	19.3%	16.4%	17.4%	17.6%	17.8%	19.2%
<b>Leverage ratio</b>								
Debt / equity (x)	0.19	0.19	0.16	0.13	0.10	0.07	0.06	0.06
<b>Market/valuation ratios</b>								
EV/Sales (x)	7.19	5.82	5.11	4.66	4.21	3.62	3.12	2.77
EV/EBITDA (x)	26.75	21.35	19.34	15.91	13.78	12.18	10.25	8.81
EPS (SAR)	5.37	6.66	6.29	7.51	8.63	9.94	12.33	14.86
BVPS (SAR)	32.41	36.33	40.55	45.80	52.10	59.55	68.55	79.40
Market price (SAR)*	174.40	167.00	167.00	167.00	167.00	167.00	167.00	167.00
Market-Cap (SAR mn)	7,821.8	7,490.0	7,476.5	7,490.0	7,490.0	7,490.0	7,490.0	7,490.0
Dividend yield	1.1%	1.2%	1.2%	1.3%	1.4%	1.5%	2.0%	2.4%
P/E ratio (x)	32.47	25.08	26.55	22.24	19.36	16.80	13.55	11.24
P/BV ratio (x)	5.38	4.60	4.12	3.65	3.21	2.80	2.44	2.10

Sources: AlJazira Capital, Company Financials





RESEARCH DIVISION

Head of Sell-Side Research - Director  
Jassim Al-Jubran  
+966 11 2256248  
j.aljabran@aljaziracapital.com.sa

RESEARCH  
DIVISION

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING  
TERMINOLOGY

1. **Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
2. **Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
3. **Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
4. **Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

## Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. This report has been written by professional employees in Al-Jazira Capital, and they undertake that neither them, nor their wives or children hold positions directly in any listed shares or securities contained in this report during the time of publication of this report, however, The authors and/or their wives/children of this document may own securities in funds open to the public that invest in the securities mentioned in this document as part of a diversified portfolio over which they have no discretion. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Investment Banking | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia, Tel: 011 2256000 - Fax: 011 2256068